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1 Picotamide was shown to inhibit platelet binding of thromboxane A2 (TxA2)-mimetics and to cause a
reduction of TxA2 platelet receptors after in vivo administration. The present study aimed to investigate
directly [3H]-picotamide binding to human platelets and in particular the relationship between binding
kinetics and antiaggregating properties.
2 [3H]-picotamide time-dependently bound to a single class of platelet TxA2 receptors with a KD of
325 nmol I` at equilibrium. The binding was displaceable by TxA2 analogues U46619 and ONO11120
(Ki 19 and 28 nmol I-I respectively) but not by prostacyclin (PGI2), prostaglandin E2 (PGE2) and TxB2.
Antiaggregating activity and TxA2 formation inhibition paralleled with binding kinetics.
3 By prolonging the incubation time from 30 to 120 min, picotamide showed a progressively increasing
non-displaceable binding, whereas specific displaceable binding decreased in comparison to the values
reached at 30 min. Non displaceable binding was specific, temperature-dependent, saturable and fol-
lowed a Michaelis-Menten kinetic (V1,app = 130 fmol per i01 platelets h-', KMaPP = 330 nmol 1-').
Picotamide progressively underwent a specific stable interaction with its platelet receptor.
4 In conclusion, after an initial reversible binding, a progressive stabilization of picotamide binding
takes place resulting in a progressively more stable interaction with platelets.
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Introduction
Picotamide (N,N'bis(3-picolyl)-4-methoxy-isophthalamide) is
a new antiaggregating drug (Violi et al., 1988; Berrettini et
al., 1990; Cattaneo et al., 1991) which was found to be able
to displace the platelet binding of both a labelled thrombox-
ane A2 (TxA2)-mimetic ([3H]-U46619) and a labelled TxA2
antagonist (['251I]-PTAOH) (Modesti et al., 1989). These find-
ings have caused picotamide to be considered as a TxA2/
PGH2 competitive receptor inhibitor (Gresele et al., 1989;
Modesti et al., 1989). However, no studies have been per-
formed aimed at investigating directly the kinetics of picota-
mide binding to the TxA2/PGH2 receptors. Moreover TxA2/
PGH2 binding sites have been found to be decreased after
picotamide administration in man (Modesti et al., 1991) and
this observation apparently contrasts with the hypothesis of
picotamide as a competitive receptor inhibitor. Indeed this
pattern might suggest either that picotamide acts as a non
competitive inhibitor with a stable interaction at the TxA2/
PGH2 receptor site, or that picotamide follows a particularly
low kinetic of dissociation from the TxA2 receptor, with
consequent functional inactivation of the TxA2 receptor.
The present study aimed to investigate directly the kinetics
of the binding of [3H]-picotamide to human platelets and to
assess the relationship between the kinetics of [3H]-picota-
mide binding and antiplatelet activity.
Methods
Platelet aggregation studies
Blood was withdrawn by venipuncture from six overnight
fasting healthy volunteers, aged 28 to 42 years, between
08 h 00 min-09 h 00 min and anticoagulated with 129 mmol
1' trisodium citrate (9:1 v:v). No subject had taken any
' Author for correspondence.
drugs for at least 15 days. Platelet aggregation studies were
performed in platelet-rich plasma (PRP) with the optical
method of Born, using an Elvi 840 dual channel aggre-
gometer (Elvi Logos, Milan, Italy). PRP was prepared by
centrifugation at 160 g at room temperature for 6 min.
Platelet poor plasma (PPP) was obtained by centrifugation of
the blood samples at 1,200 g at room temperature for 15 min.
Platelet count in PRP was adjusted to 3 x 101" platelets 1-
with autologous PPP in all experiments.
The stable endoperoxide analogue, U46619 (0.75 limol V')
and collagen (2.5 gml-') were used as inducers. Platelet
aggregation was recorded for 15 min and the extent of ag-
gregation was evaluated by measuring the maximal height
reached by the aggregation curves.
Percent inhibitions of U46619 and collagen induced plate-
let aggregation, by increasing concentrations of picotamide
(0, 0.1, 1, 10, 100, 500 and 1,000 ymoll') were calculated
from the reduction of the maximal amplitude of the aggrega-
tion tracings in relation to the values obtained in the paired
solvent experiments. The concentration of picotamide giving
50% inhibition of aggregation (ICm) was calculated from the
mean of at least four different experiments.
To assess the time-dependency of ICm, the inhibitory
effects of picotamide were evaluated after 2, 10 and 20 min of
platelet incubation with picotamide.
After 15 min stirring in the aggregometer, PRP was cen-
trifuged at 12,000 r.p.m. in an Eppendorf centrifuge and the
supernatant stored at - 20°C for TxB2 determination. TxB2
was assayed by an enzymatic immunoassay (Cayman Chemi-
cal, Ann Arbor, MI, U.S.A.). Coefficients of variation of
intraassay and inter-assay were 6.8% and 9.5%, respectively.
Binding studies
Blood sampling and platelet isolation Blood for the receptor
binding studies was withdrawn from the same healthy volun-
teers into a syringe containing indomethacin (10 ;mol 1-')
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and EDTA (5 mmol I`). PRP, obtained by centrifugation as
described above, was centrifuged at 1,800 g for 30 min at
20TC. Platelets were then resuspended in 10 ml of phosphate
buffer pH 7.2 (mmol 1-': Na2HPO4 8, NaH2PO4 2, KCl 5,
NaCI 135, EDTA 10) and again recentrifuged at 1,800 g for
30 min at 20TC. The supernatant was discarded and the
platelets were resuspended in assay Tris-buffer pH 7.4 (NaCl
100 mmol 1', dextrose 5 mmol 1- ', indomethacin 10 pmol 1-'
and Tris-HCl 5 mmol 1'). If necessary assay Tris-buffer was
added to obtain a platelet concentration of 5 x 10" platelets
1.
Equilibrium analysis of [methyleneiH]-picotamide
binding
Washed platelets (5 x 107 platelets) were incubated with 10
nmol 1' (final concentrations are given) [methylene3H]-pico-
tamide and increasing concentrations of unlabelled picota-
mide (0 to 20 jimol 1') at 22C in a final volume of 0.2 ml.
The binding obtained in the presence of a large excess of
picotamide (20 pmol I') was considered as non-specific bin-
ding. Specific binding at each concentration was calculated as
the difference between total and non-specific binding. After
30 min incubation four 4 ml aliquots of ice-cold buffer were
added to each tube to stop the reaction and the content was
rapidly filtered under reduced pressure through Whatman
GF/C glass microfibre filters. The entire washing procedure
was completed within about 15 s. Filters were dried under air
flow and counted in a Beckman gamma counter with an
overall efficiency of 50%. Binding data, dissociation constant
(KD) and maximum binding capacity (Bma), were calculated
according to Scatchard (1949).
The competition for [methylene3H]-picotamide binding by
a thromboxane A2 agonist (U46619), a thromboxane A2
antagonist (ONO1 1 120) (Narumiya et al., 1989), PGI2, PGE2,
TxB2 and picotamide were evaluated by incubating 10 nmol
1-' [methylene3H]-picotamide with platelets in the absence
and in the presence of increasing concentrations (20 nmol
['-2 mmol 1') of competitors in a final volume of 0.2 ml.
After 30 min the incubation was stopped by the addition of
5 ml of cold assay buffer and filtered. Inhibition constants of
competitors were calculated according to Cheng & Prusoff
(1973).
Kinetic analysis of [methylene3H]-picotamide specific
binding
The kinetics of association and dissociation of [methylene3H]-
picotamide to washed platelets were evaluated as previously
described for other TxA2 antagonists (Modesti et al., 1989).
To determine the rate of association of [methylene3H]-pico-
tamide, 5 x I07 washed platelets were suspended in assay
buffer containing 10 nmol l- [methylene3H]-picotamide (at
22°C in a final volume of 0.2 ml. After selected time intervals
of incubation (20 s, 1, 2, 3, 5, 10, 15, 20, 30 min) samples
were rapidly filtered. Specific binding was determined as the
difference between the amount of [methylene3H]-picotamide
bound in the absence and in the presence of unlabelled
picotamide (20 jimol 1').
To determine the rate of dissociation of [methylene3H]-
picotamide from its platelet binding sites, samples were
prepared as described above. After 30 min incubation, pico-
tamide (20 gmol 1') was added, and the amount of specific
binding was measured after various time periods (20 s, 1, 2,
3, 5, 10, 15, 20, 30 min). Kinetic constants were calculated
according to Weiland & Molinoff (1981).
Effect ofprolonged incubation on
[methylene3H]-picotamide displaceable and non
displaceable binding
The time-dependency of [methylene3H]-picotamide displace-
able and non displaceable binding was investigated in separ-
ate time course experiments.
The total, displaceable specific, non displaceable specific
and non-specific binding at the different incubation times
were investigated at 37°C by preparing three different sets of
tubes.
The first set of tubes was aimed to evaluate the total
binding. Tubes containing [methylene3H]-picotamide at in-
creasing concentrations (10-9, 10-8, 5 x 10-8, 10-7, 5 x 10-7,
10-6, 10-' mol [I) plus platelets, were prepared as described
above and filtered after different incubation times (t) (3, 10,
20, 30, 50, 60 and 120min of incubation).
The second set of tubes was prepared to evaluate the non
specific binding. Tubes contained the same incubation mix-
ture (increasing concentrations of [methylene3H]-picotamide
and platelets) plus a high concentration (20 gmol 1`) of
unlabelled picotamide added before starting incubation (time
0). Samples were filtered after different incubation times (t)
contemporary to the first set of tubes (3, 10, 20, 30, 50, 60
and 120 min of incubation).
In the third set of tubes, containing platelets and increas-
ing concentrations of [methylene3H]-picotamide, a large ex-
cess of unlabelled picotamide (20 tmol I') was added at
each time t (3, 10, 20, 30, 50, 60 and 120 min of incubation).
Samples were filtered after 30 min and the residual binding
was considered as non displaceable binding. The difference
between total and non displaceable binding was considered
as displaceable specific binding (displaceable receptor bin-
ding). The difference between non displaceable and non-
specific (evaluated by the addition of 20 fmol 1' picotamide
at time 0) binding was considered as specific non displaceable
binding (non displaceable receptor binding).
The characteristics (KD, Bma,) of displaceable specific recep-
tor binding at 37°C after 30 min (at equilibrium) and after 60
and 120 min of incubation were calculated according to Scat-
chard (1949) as previously described.
The affinity constant (KMapp) and the maximal velocity
(Vmaxapp) of non-displaceable specific binding were calculated
for each subject by the double reciprocal plot of Lineweaver-
Burk (Comish-Bowden & Eisenthal, 1978) and the lines of
best fit were calculated by linear regression using the method
of the least squares.
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Figure 1 Platelet aggregation induced by U46619 (0.75 pmol 1-') (a)
and collagen (2.5 gg ml ') (b) with increasing concentrations of
picotamide after different incubation times: (0) 2min incubation;
(A) 10 min incubation; (O) 20 min incubation.
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The competition for [methylene3H]-picotamide non-displa-
ceable binding by picotamide, ONOl 1120, U46619, PGI2,
PGE2 and TxB2, was evaluated by incubating 10 nmol 1-'
[methylene3H]-picotamide with 5 x 107 platelets in the absen-
ce and in the presence of increasing concentrations (20 nmol
1'-2 mmol 1') of competitors (added at time 0) at 370C in
a final volume of 0.2 ml. After 60 min the incubation was
stopped by the addition of 5 ml of cold assay buffer and
platelets were spun down by centrifugation. The pellet was
then resuspended in assay buffer and filtered. Incorporated
radioactivity was then counted as described.
Materials
ONOI 1120 (9,1 1-dimethylmethano-I 1,12-methane-i 6-phenyl-
13, 14-dihydro-13-aza-1 5-tetranor-TxA2) (Narumiya et al.,
1986) was a kind gift from Prof. Narumiya (Kyoto, Japan).
Prostacyclin (PG12), PGE2 and thromboxane B2 (TxB2) were
obtained from Upjohn, Kalamazoo, MI, U.S.A. U46619
(9,11-dideoxy-11 a,9-x-epoxymethano-PGF2.) was obtained
from SIGMA Chemicals, St. Louis, MO, U.S.A. Picotamide
(N, N'bis (3-picolyl)-4-methoxy-isophthalamide, batch no.
870311) was kindly provided by the Samil Inc. (Sandoz
group, Rome, Italy); [methylene3H]-picotamide (29 Ci mmol
1-1, Amersham, Buckinghamshire, GB) was a kind gift of
LPB (Milan, Italy).
All the other reagents were obtained from Merck (Darm-
stadt, Germany) and were of analytical grade.
[Methylene3H]-picotamide binding
Equilibrium studies The binding of [methylene3H]-picota-
mide at 220C was saturable. Scq-Thard analysis of specific
binding at equilibrium (i.e. after 30 min incubation) yielded a
straight line, indicating a single class of binding sites for
picotamide with KD of 325 nmol 1- and a Bmax of 312 fmol
per 108 platelets (Figure 3). The Hill coefficient (nH) was 1.12
(Figure 4), suggesting that picotamide binds to a homogen-
eous individual class of binding sites without cooperativity.
.C
V 250
°CD 200 - 8>
* 010 02 .,_
CD
-E5 S 0.050 # 0 50 150 250 350
CD : B (fmol per 108 pIt)
0 500 1000 1500 2000
[3H1-picotamide (nmol 1-1)
Figure 3 Saturation curve of the (methylene3H]-picotamide binding
to washed human platelets (fmol per 108 platelets) at 22°C. Scatchard
analysis of the specific binding.
Results 100.
Aggregation studies
After 2 min of incubation, picotamide dose-dependently in-
hibited platelet aggregation induced both by collagen and
U46619 with IC50s of 4.5 x 10-4moll1' and 6.1 x 10-4mol
1- respectively. Inhibition of platelet aggregation was also
time-dependent and peaked after 20 min. Picotamide IC50 on
collagen-induced platelet aggregation were 6.8 x 10-5 mol 1-'
and 3.7 x 10-6 mol [' after 10 and 20 min of incubation
respectively. Picotamide IC50 on U46619-induced aggregation
was 5.9 xl0-5moll and 4.7 x l06molIh' after 10 and
20 min of incubation respectively (Figure 1).
Picotamide also exerted a time-dependent inhibitory activ-
ity on TxA2 production. The EC50s for TxA2 production
during collagen (7.5 fg ml-') induced aggregation were
5.4 x 10-5 mol 1', 2.2 x 10-6 mol 1' and 4.3 x 10' mol 1'I
after 2, 10 and 20 min of incubation respectively (Figure 2).
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Figure 2 Effect of increasing concentrations and time of incubation
of picotamide on thromboxane B2 (TxB2) synthesis by platelets dur-
ing collagen induced (7.5 jug ml- ) aggregation: (0) 2 min incuba-
tion; (A) 10 min incubation; (@) 20 min incubation.
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Figure 4 (a) Displacement of the specific [methylene3H]-picotamide
binding by increasing concentrations of different compounds: (U)
U46619; (A) ONO11120; (0) picotamide; (0) TxB2; (A) PGE2; (@)
PGI2. Data points represent means of triplicate determinations in at
least four independent experiments. (b) Hill plot of the displacement
curve by picotamide.
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Binding of [methylene3HJ-picotamide was displaced by un-
labelled picotamide, ONO 1120 and by U46619 with a Ki of
361 nmol 1-l, 28 nmol 1-l and 19 nmol 1-' respectively. In
contrast, PGI2, PGE2 and TxB2 did not inhibit the binding
(Figure 4).
Kinetic analysis The displaceable specific binding of [methy-
lene3H]-picotamide to platelets reached equilibrium after
about 30 min. The observed rate constant of association
(KobS) was 0.110 min' . The dissociation curve performed
after 30 min of incubation showed a displacement of about
65-70% of the total radioactivity bound. The analysis of the
first order rate of dissociation showed a linear pattern with a
K_, of 0.107 min-' (n = 6). The resulting association rate
constant (k1) was 0.00028 nmol 1Imin' with a calculated
dissociation constant (KD) of 382 nmol 1' (Figure 5).
When the displaceable specific binding of [methylene3H]-
picotamide to platelets at 370C was investigated after 30, 60
and 120 min, a progressive significant reduction of the bin-
ding capacity was observed. The Bm. were 343, 243 and
153 fmol per 108 platelets after 30, 60 and 120 min respec-
tively (2066, 1463, 921 binding sites/platelet respectively) with
no significant changes in KD (275, 251 and 222 nmol I1
respectively) (Figure 6), thus indicating a progressive decrease
of platelet receptors.
In contrast the non displaceable binding of [methylene3H]-
picotamide to platelets (i.e. the residual radioactivity after
addition of 20 ,Lmol 1 picotamide to platelets at each time)
at 37C showed a slow regular increase (Figure 7). This
time-dependent increase of non displaceable binding was
almost completely inhibited when binding was performed at
4°C. The non displaceable binding of [methylene3H]-pico-
tamide did not increase when unlabelled picotamide was
added at time 0 (non specific binding) (Figure 7).
The non displaceable binding at 37C was concentration-
dependent as it increased with increasing concentrations of
[methylene3H]-picotamide but was saturable. In fact, a pro-
gressive increase in binding velocity was found until a plateau
level was reached with a Michaelis-Menten type kinetic of
saturation (Figure 8). The Lineweaver-Burk plot was found
to be linear (Figure 8) with a V,,app of 130 fmol per 108
platelets h'- and a KMapp of 330 nmolI 1. Therefore, about
35% of [methylene3H]-picotamide bound to platelet receptors
was irreversibly bound after 1 h.
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Figure 5 Time course of the association and dissociation phases of
the specific [methylene3H]-picotamide binding to washed human
platelets at 22°C. Dissociation was obtained after 30 min incubation
upon addition of 20 ,mol I-I (final concentration) picotamide to the
incubation mixture. Data points represent means of triplicate deter-
minations in at least four independent experiments. Upper inset:
Specific binding association is plotted according to the pseudo-first
order rate equation (y = 0.331 + 0.1 lOx; k0b = 0.110 min-). Lower
inset: Dissociation is plotted as a first order reaction
(y =-0.461-0.107x; k.1 = 0.107 min-1; kl = 0.00028 nmol ml1
min-'; KD + 382 nmol 1').
The non displaceable binding of [methylene3H]-picotamide
was inhibited by unlabelled picotamide, ONOl 1120 and
U46619 when added at time 0 but not by PGI2, PGE2 and
TxB2 (data not shown).
Discussion
The present results indicate that [methylene3H]-picotamide
binds time-dependently to specific TxA2/PGH2 platelet recep-
tors from which it is displaced by the TxA2 agonist, U46619
and antagonist, ONO11120. Moreover, the time-dependent
picotamide binding is associated with a progressive reduction
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Figure 6 Saturation curve (a) and Scatchard analysis (b) of the
specific [methylene3H]-picotamide binding to washed human platelets
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Figure 7 Time course of the binding of [methylene3H]-picotamide1Onmol -' to washed human platelets (plt) at 37°C. Total binding(0); specific displaceable binding at indicated time (t) (U) was
considered as the radioactivity displaced by adding picotamide 20
pmoll-1 (final concentration) at time (t). Specific non-displaceable
binding was defined as the difference between non displaceable bin-
ding (0) and non-specific binding (@).
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Figure 8 Analysis of the [methylene3H]-picotamide uptake by hum-
an platelets (pit) in experiments performed at 37C. Results shown
are the means of experiments carried out in triplicate. Inset: Line-
weaver-Burk's plot of the results.
in displaceable binding and a contemporary increase of
specific non-displaceable binding.
These findings confirm previous indirect studies which had
shown that picotamide shares the TxA2/PGH2 receptor (Mo-
desti et al., 1989). In addition they show that both the
picotamide binding and the antiaggregating activity of pico-
tamide occur slowly, reaching their maximum level after
about 20 min incubation. The slow onset of picotamide bin-
ding accounts for the apparently low in vitro antiaggregating
activity reported in previous studies (Gresele et al., 1989;
Berrettini et al., 1990) in which the antiaggregating effect was
assessed after only 2-O min incubation, i.e. before that the
binding equilibrium was reached.
The antiaggregating activity of picotamide is associated
with reduced TxA2 formation which may be due both to
inhibition of TxA2-synthase by picotamide (Gresele et al.,
1989) and to the reduced platelet aggregation resulting from
TxA2 receptor blockade. Indeed, TxA2 formation during
collagen-induced platelet aggregation was found to be red-
uced by the simple receptor antagonists not provided with
TxA2 synthase inhibitory properties (Hornby & Skidmore,
1984).
Previous studies on the antiaggregating effects of picota-
mide (Gresele et al., 1989; Berrettini et al., 1990) led to the
suggestion that picotamide could act as a competitive TxA2
inhibitor. However, the present kinetic analysis of the [meth-
ylene3H]-picotamide binding showed a more complex pattern.
Indeed [methylene3H]-picotamide was readily and almost
completely displaced from the TxA2 receptor during the first
20 min of incubation whereas after the first 20 min the non
displaceable amount progressively increased and paralleled
the reduction of specific binding. This pattern conformed to
that of non-competitive receptor inhibitors (Patscheke, 1990)
and suggests a stable interaction of picotamide with the TxA2
platelet receptor. The progressively increasing non displace-
able binding of picotamide is unlikely to be due to a simple
diffusion of the drug into the platelets because the non
displaceable binding of [methylene3H]-picotamide was satur-
able, reached a plateau and was specifically blocked by the
addition of unlabelled picotamide. The non displaceable bin-
ding was found to be almost completely inhibited when the
binding experiments were performed at 40C. This fact and the
observation that the KM of the specific non reversible binding
was in the same order of magnitude of the receptor binding
KD, are indicative of an internalization of the TxA2 receptor-
picotamide complex, although a simple non reversible recep-
tor blockade cannot be excluded. Previous studies reported
evidence of internalization of the TxA2 receptor after the
binding of ONOI 1120 (an antagonist of TxA2) in human
platelets (Modesti et al., 1990) and U46619 (a TxA2-mimetic)
in cultured human leukaemic cells (Dorn, 1991).
In conclusion, picotamide binds to the TxA2 receptor on
human platelets with peculiar kinetics. After a first stabilizing
period when the binding of picotamide is still reversible, a
progressive stabilization of the binding takes place, resulting
in an irreversible receptor blockade. For these characteristics
picotamide is to be considered an inhibitor of platelet activity
displaying both competitive and non competitive activity
against thromboxane A2-mediated responses.
This work was supported in part by a grant from Consiglio Naz-
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